DIKUL - logo

Rezultati iskanja

Osnovno iskanje    Izbirno iskanje   
Iskalna
zahteva
Knjižnica

Trenutno NISTE avtorizirani za dostop do e-virov UL. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 224.330
11.
  • Pre-Clinical Development of... Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
    Liu, Jie; Wang, Lijuan; Zhao, Feifei ... PloS one, 09/2015, Letnik: 10, Številka: 9
    Journal Article
    Recenzirano
    Odprti dostop

    CD47 is a widely expressed cell surface protein that functions as a regulator of phagocytosis mediated by cells of the innate immune system, such as macrophages and dendritic cells. CD47 serves as ...
Celotno besedilo
Dostopno za: UL

PDF
12.
  • Safety and Efficacy of Durv... Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
    Kelly, Ronan J; Lee, Jeeyun; Bang, Yung-Jue ... Clinical cancer research, 02/2020, Letnik: 26, Številka: 4
    Journal Article
    Recenzirano
    Odprti dostop

    This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal ...
Celotno besedilo
Dostopno za: CMK, UL

PDF
13.
Celotno besedilo
Dostopno za: UL

PDF
14.
  • Particle shape enhances spe... Particle shape enhances specificity of antibody-displaying nanoparticles
    Barua, Sutapa; Yoo, Jin-Wook; Kolhar, Poornima ... Proceedings of the National Academy of Sciences, 02/2013, Letnik: 110, Številka: 9
    Journal Article
    Recenzirano
    Odprti dostop

    Monoclonal antibodies are used in numerous therapeutic and diagnostic applications; however, their efficacy is contingent on specificity and avidity. Here, we show that presentation of antibodies on ...
Celotno besedilo
Dostopno za: UL

PDF
15.
  • Monovalent antibody design ... Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
    Merchant, Mark; Ma, Xiaolei; Maun, Henry R ... Proceedings of the National Academy of Sciences, 08/2013, Letnik: 110, Številka: 32
    Journal Article
    Recenzirano
    Odprti dostop

    Binding of hepatocyte growth factor (HGF) to the receptor tyrosine kinase MET is implicated in the malignant process of multiple cancers, making disruption of this interaction a promising therapeutic ...
Celotno besedilo
Dostopno za: UL

PDF
16.
  • Interleukin‐6 blocking agen... Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
    Boutron, Isabelle; Ghosn, Lina; Chaimani, Anna ... Cochrane database of systematic reviews, 03/2021, Letnik: 2021, Številka: 3
    Journal Article
    Recenzirano
    Odprti dostop

    Background Interleukin 6 (IL‐6) blocking agents have been used for treating severe coronavirus disease 2019 (COVID‐19). Their immunosuppressive effect might be valuable in patients with COVID‐19 ...
Celotno besedilo
Dostopno za: VSZLJ
17.
  • Tildrakizumab (MK-3222), an... Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
    Papp, K.; Thaçi, D.; Reich, K. ... British journal of dermatology (1951), 10/2015, Letnik: 173, Številka: 4
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Tildrakizumab is a high‐affinity, humanized, IgG1/κ, anti‐interleukin (IL)‐23p19 monoclonal antibody that does not bind human IL‐12 or p40 is being developed for the treatment of ...
Celotno besedilo
Dostopno za: UL

PDF
18.
  • Lenvatinib plus Pembrolizum... Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert; Alekseev, Boris; Rha, Sun-Young ... The New England journal of medicine, 04/2021, Letnik: 384, Številka: 14
    Journal Article, Web Resource
    Recenzirano
    Odprti dostop

    Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib ...
Celotno besedilo
Dostopno za: CMK, UL

PDF
19.
  • Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial
    Kimball, Alexa B; Kerdel, Francisco; Adams, David ... Annals of internal medicine, 12/2012, Letnik: 157, Številka: 12
    Journal Article
    Recenzirano

    Hidradenitis suppurativa (HS) is a chronic, painful skin disease characterized by abscesses, nodules, and draining fistulas in the axilla and groin of young adults. To evaluate the efficacy and ...
Preverite dostopnost
20.
  • Phage Display Technology as... Phage Display Technology as a Powerful Platform for Antibody Drug Discovery
    Nagano, Kazuya; Tsutsumi, Yasuo Viruses, 01/2021, Letnik: 13, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Antibody drugs with a high affinity and specificity are effective and safe for intractable diseases, such as cancers and autoimmune diseases. Furthermore, they have played a central role in drug ...
Celotno besedilo
Dostopno za: UL

PDF
1 2 3 4 5
zadetkov: 224.330

Nalaganje filtrov